AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33159275 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (RIC) with post-transplantation cyclophosphamide (PTCy) and mycophenolate mofetil and tacrolimus for GVHD prophylaxis.
Number of subjects: 25
Study 33159365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisantrene (250 mg/m2)
Number of subjects: 10
Study 33159841 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Number of subjects: 0
Study 33159841 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Number of subjects: 0
Study 33159841 — intervention group
Group type: COMPARATOR
Intervention: Background therapy
Number of subjects: 0
Study 33160031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting serum copeptin measured by high-sensitivity ELISA
Number of subjects: 112
Study 33160031 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without aPAD)
Number of subjects: 112
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort study
Number of subjects: 200
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation using the 10-point Cognitive Screener (10-CS)
Number of subjects: 200
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment using Fried index score
Number of subjects: 200
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment (body composition assessment, global subjective assessment, dietary intake)
Number of subjects: 200
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities assessment using Charlson comorbidity index
Number of subjects: 200
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers including FGF-23 and Klotho
Number of subjects: 200
Study 33160321 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational follow-up for at least 12 months
Number of subjects: 200
Study 33160339 — intervention group
Group type: EXPERIMENTAL
Intervention: MeTree risk assessment program
Number of subjects: 1889
Study 33160342 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based training session utilizing a novel low-cost simulator made with gelatin, water, and psyllium fiber for three hours.
Number of subjects: 60
Study 33160342 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based training session
Number of subjects: 60
Study 33160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia (measured by the Tampa Scale)
Number of subjects: 269
Study 33160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional performance (measured by the Iowa Level of Assistance scale)
Number of subjects: 269
Study 33160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative functional ability (measured by the Western Ontario and McMaster Osteoarthritis Index)
Number of subjects: 269
Study 33160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics (age, sex, body mass index)
Number of subjects: 269
Study 33160701 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h Urinary magnesium concentration (24 h UMg)
Number of subjects: 3179
Study 33160701 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3179
Study 33160700 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 survivors
Number of subjects: 213
Study 33160700 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 survivors with weight loss
Number of subjects: 213
Study 33160848 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) imaging
Number of subjects: 213
Study 33160848 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 213
Study 33161007 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) applied at home, 2-3 times/day during bowel regimen
Number of subjects: 5
Study 33161007 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) during bowel routine
Number of subjects: 5
Study 33161013 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET-based dose-painting technique with SIB-IMRT and concomitant Cisplatin after 2 cycles of induction chemotherapy.
Number of subjects: 29
Study 33161160 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal fluid microbiome of patients with PDAC
Number of subjects: 308
Study 33161160 — intervention group
Group type: COMPARATOR
Intervention: Duodenal fluid microbiome of control subjects and patients with pancreatic cyst(s)
Number of subjects: 308
Study 33161240 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab (IV administration, 900 to 2000 mg every two weeks in dose-escalation phase, optimal biological dose of 1000 mg in dose-expansion phase)
Number of subjects: 63
Study 33161240 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Number of subjects: 63
Study 33161258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant (Slim Modiolar) with bimodal stimulation (cochlear implant and hearing aid in contralateral ear) for 6-months postimplant
Number of subjects: 100
Study 33161258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal condition (cochlear implant and hearing aid)
Number of subjects: 100
Study 33161492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 422
Study 33161492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 422
Study 33161492 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 422
Study 33161777 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic current-induced vasodilation (CIV) in patients under low-dose aspirin (ASA; ≤ 500 mg/day)
Number of subjects: 822
Study 33161777 — intervention group
Group type: COMPARATOR
Intervention: Galvanic current-induced vasodilation (CIV) in patients not under low-dose aspirin (ASA; ≤ 500 mg/day)
Number of subjects: 822
Study 33161846 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA (serum amyloid A) levels on admission
Number of subjects: 650
Study 33161899 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-independent score of ≥ 4
Number of subjects: 2838
Study 33161899 — intervention group
Group type: COMPARATOR
Intervention: WHO eligibility criteria (EC)
Number of subjects: 2838
Study 33161899 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-independent score categorized into low (< 4), moderate (4-6), and high risk (≥ 7)
Number of subjects: 2838
Study 33161899 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-dependent score
Number of subjects: 2838
Study 33163109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus™ home-based exercise program, 3 times a week for 30 min for 24 weeks
Number of subjects: 0
Study 33163394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside monosialic acid (GM1)
Number of subjects: 55
Study 33163394 — intervention group
Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 55
Study 33163408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation therapy
Number of subjects: 0
Study 33163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody positivity defined as a dual-positive response against both the receptor-binding domain and nucleocapsid proteins of SARS-CoV-2.
Number of subjects: 15771
Study 33163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody surveillance in children during 2020.
Number of subjects: 15771
Study 33163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody prevalence from April 2020.
Number of subjects: 15771
Study 33163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission in children with virus-positive family members.
Number of subjects: 15771
Study 33163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic positive children.
Number of subjects: 15771
Study 33163984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody frequency in newborns.
Number of subjects: 15771
Study 33164349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg SC every 2 weeks (Q2W)
Number of subjects: 175
Study 33164349 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from IV to SC sarilumab 200 mg SC Q2W
Number of subjects: 175
Study 33164349 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing sarilumab 200 mg SC Q2W
Number of subjects: 175
Study 33164633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 12764
Study 33164633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 12764
Study 33164633 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥65 years and use of diuretics at discharge
Number of subjects: 12764
Study 33164985 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue oxygen partial pressure (pO2) measurement in MHL, MHO, and MUO groups.
Number of subjects: 46
Study 33164985 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue pO2 measurement.
Number of subjects: 46
Study 33164985 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PAI-1 concentration measurement.
Number of subjects: 46
Study 33164985 — intervention group
Group type: COMPARATOR
Intervention: Plasma concentrations of other cytokines and chemokines measurement.
Number of subjects: 46
Study 33164993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 33164993 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 33164993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 33164993 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 0
Study 33165001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose haemodialysis
Number of subjects: 0
Study 33165001 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis
Number of subjects: 0
Study 33165001 — intervention group
Group type: EXPERIMENTAL
Intervention: Deintensification of haemodialysis treatment
Number of subjects: 0
Study 33165001 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose haemodialysis
Number of subjects: 0
Study 33165027 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 18229
Study 33165027 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 18229
Study 33165120 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Perceived Access to Care (APAC)
Number of subjects: 1004
Study 33165755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (79.2%)
Number of subjects: 1021
Study 33165755 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivirals (67.6%)
Number of subjects: 1021
Study 33165755 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 1021
Study 33165755 — intervention group
Group type: COMPARATOR
Intervention: Age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, O2 saturation < 92%, elevated C reactive protein
Number of subjects: 1021
Study 33165773 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg single dose)
Number of subjects: 34
Study 33165773 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg single dose) after dialysis (P1)
Number of subjects: 34
Study 33165773 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg single dose) before dialysis (P2)
Number of subjects: 34
Study 33166419 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 4740
Study 33166419 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 4740
Study 33166419 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine and insulin detemir
Number of subjects: 4740
Study 33167024 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-ibrutinib induction for 9 months followed by ibrutinib for 6 additional months in patients with complete remission and BM MRD <0.01% (n = 10)
Number of subjects: 135
Study 33167024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine/cyclophosphamide-obinutuzumab immunochemotherapy for 4 cycles in patients with partial remission and/or BM MRD ≥0.01% (n = 120)
Number of subjects: 135
Study 33167773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day)
Number of subjects: 20
Study 33167995 — intervention group
Group type: COMPARATOR
Intervention: Highest quintile of organic food (OF) consumption
Number of subjects: 33256
Study 33167995 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment of 5% in the proportion of OF in the diet
Number of subjects: 33256
Study 33168134 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease
Number of subjects: 26
Study 33168134 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without atherosclerosis)
Number of subjects: 26
Study 33168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume assessed by computed tomography
Number of subjects: 0
Study 33168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteome of EAT assessed by SWATH-MS mass spectrometry
Number of subjects: 0
Study 33168363 — intervention group
Group type: COMPARATOR
Intervention: Mediastinal and subcutaneous adipose tissue
Number of subjects: 0
Study 33168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating and local adipose tissue-derived biomarkers of CAD
Number of subjects: 0
Study 33168556 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with older adults and caregivers
Number of subjects: 30
Study 33168556 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey for interdisciplinary health and social care providers
Number of subjects: 30
Study 33168612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (NF) treatment; children received 10 to 15 mg/kg/day for 60 to 90 days; adults received 8 to 10 mg/kg/day for 30 days
Number of subjects: 320
Study 33168654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4827
Study 33168654 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes support and education (DSE)
Number of subjects: 4827
Study 33168818 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of unconjugated antibody with panitumumab-IRDye800CW
Number of subjects: 0
Study 33168818 — intervention group
Group type: COMPARATOR
Intervention: Panitumumab-IRDye800CW alone
Number of subjects: 0
Study 33169372 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release surgery in people with diabetes (n=27)
Number of subjects: 66
Study 33169372 — intervention group
Group type: COMPARATOR
Intervention: Carpal tunnel release surgery in people without diabetes (n=30)
Number of subjects: 66
Study 33169372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (people with and without diabetes)
Number of subjects: 66
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation with low tidal volume (median 6.3 mL/kg predicted bodyweight, IQR 5.7-7.1)
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatments for refractory hypoxaemia
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-free days at day 28
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ventilation
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ICU and hospital stay
Number of subjects: 553
Study 33169671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 553
Study 33169839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 7817
Study 33169859 — intervention group
Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 2378
Study 33169859 — intervention group
Group type: EXPERIMENTAL
Intervention: Divorced patients
Number of subjects: 2378
Study 33169859 — intervention group
Group type: EXPERIMENTAL
Intervention: Widowed patients
Number of subjects: 2378
Study 33169859 — intervention group
Group type: EXPERIMENTAL
Intervention: Health perception quartiles
Number of subjects: 2378
Study 33169859 — intervention group
Group type: COMPARATOR
Intervention: Secondary or primary education
Number of subjects: 2378
Study 33169859 — intervention group
Group type: COMPARATOR
Intervention: Presence of depression
Number of subjects: 2378
Study 33170131 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (SB Colonoscopy Prep)
Number of subjects: 46
Study 33170131 — intervention group
Group type: COMPARATOR
Intervention: Written instructions
Number of subjects: 46
Study 33170310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafedrine/Theodrenaline (C/T)
Number of subjects: 1496
Study 33170310 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (E)
Number of subjects: 1496
Study 33170484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimasertib (dose range 1-255 mg/day)
Number of subjects: 180
Study 33170486 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment
Number of subjects: 0
Study 33170486 — intervention group
Group type: COMPARATOR
Intervention: Arachidonic acid (AA)
Number of subjects: 0
Study 33170593 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional analysis of human metastatic uveal melanoma from tumor samples collected in a prospective phase II trial (A091201)
Number of subjects: 0
Study 33170593 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional data analysis suggesting PI3K/mTOR and glycolysis pathways
Number of subjects: 0
Study 33171129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground ambulation training using a powered exoskeleton (ReWalk) for 40 sessions, 3 times per week, each session lasting up to 2 hours.
Number of subjects: 8
Study 33171144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-chromosome gene content and regulation
Number of subjects: 0
Study 33171144 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging studies
Number of subjects: 0
Study 33171487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine 300 mg once per day on days 1 to 14 and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days
Number of subjects: 25
Study 33171487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine and romidepsin
Number of subjects: 25
Study 33171854 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 20
Study 33171854 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated seasonal influenza vaccination
Number of subjects: 20
Study 33172323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasotuxizumab
Number of subjects: 0
Study 33172424 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-PD diagnosis
Number of subjects: 221
Study 33172424 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-PD treatment (antibiotics)
Number of subjects: 221
Study 33172424 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan changes
Number of subjects: 221
Study 33172424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectasis Severity Index (BSI)
Number of subjects: 221
Study 33172444 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable prediction model based on 8 variables (age, race, insurance, GINI income inequality, long-term anticoagulant use, receipt of a flu vaccine in the past year, frequency of missed clinic appointments, and clinic site)
Number of subjects: 1596
Study 33172772 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 103
Study 33172881 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus gemcitabine and oxaliplatin (GEMOX)
Number of subjects: 38
Study 33172887 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody testing
Number of subjects: 992
Study 33172948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid biomarkers (plasma/microdialysate neurofilament light)
Number of subjects: 250
Study 33172948 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging biomarkers (diffusion tensor MRI)
Number of subjects: 250
Study 33172948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical, cognitive and functional outcome measures
Number of subjects: 250
Study 33173161 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ruxolitinib plus steroid
Number of subjects: 0
Study 33173916 — intervention group
Group type: EXPERIMENTAL
Intervention: Centhaquine (0.01 mg/kg) in 100 mL normal saline infusion over 1 hour
Number of subjects: 105
Study 33173916 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline) in 100 mL infusion over 1 hour
Number of subjects: 105
Study 33174185 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics as a diagnostic tool
Number of subjects: 0
Study 33174479 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK1 expression in vitiligo patients' skin
Number of subjects: 24
Study 33174479 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK3 expression in vitiligo patients' skin
Number of subjects: 24
Study 33174479 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK2 expression in vitiligo patients' skin
Number of subjects: 24
Study 33174479 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of JAK1 and JAK3 expression levels with disease activity and severity
Number of subjects: 24
Study 33174479 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective JAK3/1 inhibition
Number of subjects: 24
Study 33175184 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD/(VI+TOD) ratio
Number of subjects: 482
Study 33175184 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI score
Number of subjects: 482
Study 33175184 — intervention group
Group type: EXPERIMENTAL
Intervention: PDI score
Number of subjects: 482
Study 33175262 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivisceral resection (MVR)
Number of subjects: 58
Study 33175338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 16
Study 33175411 — intervention group
Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 1729